Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor…
Roches Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
Vabysmo PFS is the first and only prefilled syringe containing a bispecific…